NJBIZ

Cellares enters into agreement with biopharma Kite

Cellares announced Thursday an agreement with Kite to evaluate its automated manufacturing platform, the Cell Shuttle. NJBIZ has reported on Cellares. Earlier this year, the first Integrated ...
NJBIZ

Cellares cuts the ribbon on Bridgewater smart factory facility

During a Jan. 29 ribbon cutting for the company’s new Somerset County location, Cellares CEO and co-founder Fabian Gerlinghaus described the facility’s magnitude. “Bridgewater is such an important ...
Business Wire

Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer

Appointment positions Cellares to scale globally, deliver on existing commercial contracts, and meet rapidly growing customer demand Eissa brings 20+ years of biopharma leadership experience to ...
GEN

Cellares and Lyell Evaluate CAR T-Cell Automated Manufacturing

Lyell Immunopharma will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program. As part of the collaboration, the ...
Morningstar

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence ProT-096 designed to address critical gaps in immune ...
Yahoo Finance

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Morningstar

Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies

Collaboration with Stanford Medicine establishes a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases ...
Business Wire

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, ...
GEN

Cellares to Automate Manufacturing and Release Testing for Gene-Edited HSC Therapies for Stanford Medicine

Cellares will collaborate with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for ...
Nasdaq

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Soleymannezhad brings more than two decades of experience building global commercial organizations around advanced life-science platforms. At MaxCyte, he led commercial strategy and execution across ...
News Medical

Cellares to expand automated manufacturing to gene-edited stem cell therapies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford ...